Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Charmacy Pharmaceutical Co., Ltd. (2289.HK)
Shantou, CN
Charmacy Pharmaceutical Co., Ltd. serves as a prominent distributor of pharmaceutical products across the People's Republic of China. The company's comprehensive portfolio includes Western medications, traditional Chinese patent medicines, and various healthcare items, along with associated advisory services. These are supplied to both wholesale distributors and retail pharmacies. Furthermore, Charmacy operates "Charmacy e-Medicine," its proprietary B2B digital platform, which enables clients to efficiently place orders, make inquiries, and process payments online. Founded in 1984, the firm maintains its headquarters in Shantou, PRC. It was formerly known as Chuangmei Pharmaceutical Co., Ltd. until its official renaming to Charmacy Pharmaceutical Co., Ltd. in July 2016.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -6.01% | -6.01% | -5.69% | -21.97% | -24.97% | -25.07% | -31.63% | -5.69% | -38.75% | -31.63% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%-1.2% Q4'25: +4.5% (vs Q4'23)
-
EPS growth Medical - Distribution: +4.9%-12.2% Q4'25: -4.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+1.7% ★ Q4'25: +0.0% (vs Q4'23)
-
EBIT margin Medical - Distribution: +3.0%+3.0% Q4'25: +2.8% (vs Q4'23)
-
ROIC Medical - Distribution: +5.7%+4.9% Q4'25: +10.0% (vs Q4'23)
-
Share dilution Medical - Distribution: +0.0%+0.0% Q4'25: 0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×13.74× Q4'25: 7.14× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
4.10B
est: 4.09B (+0.2%)
|
3.94B
est: 4.98B (-21.0%)
|
3.49B
est: 6.15B (-43.2%)
|
3.99B
est: 6.90B (-42.2%)
|
4.38B
est: 4.35B (+0.7%)
|
5.34B
5.34B – 5.34B
+22.8% YoY
|
6.27B
6.27B – 6.27B
+17.4% YoY
|
7.37B
7.37B – 7.37B
+17.5% YoY
|
| EBITDA |
99.39M
est: 123.74M (-19.7%)
|
113.81M
est: 150.70M (-24.5%)
|
109.41M
est: 186.22M (-41.2%)
|
111.03M
est: 208.93M (-46.9%)
|
152.14M
est: 146.84M (+3.6%)
|
180.27M
180.27M – 180.27M
+22.8% YoY
|
211.65M
211.65M – 211.65M
+17.4% YoY
|
248.60M
248.60M – 248.60M
+17.5% YoY
|
| EBIT |
85.24M
est: 97.09M (-12.2%)
|
94.75M
est: 118.24M (-19.9%)
|
85.47M
est: 146.10M (-41.5%)
|
86.48M
est: 163.92M (-47.2%)
|
131.54M
est: 188.36M (-30.2%)
|
231.25M
231.25M – 231.25M
+22.8% YoY
|
271.50M
271.50M – 271.50M
+17.4% YoY
|
318.90M
318.90M – 318.90M
+17.5% YoY
|
| Net Income |
44.76M
est: 57.93M (-22.7%)
|
45.43M
est: 62.23M (-27.0%)
|
40.15M
est: 84.52M (-52.5%)
|
40.56M
est: 97.66M (-58.5%)
|
46.27M
est: 61.68M (-25.0%)
|
66.80M
66.80M – 66.80M
+8.3% YoY
|
86.19M
86.19M – 86.19M
+29.0% YoY
|
104.27M
104.27M – 104.27M
+21.0% YoY
|
| SGA |
117.58M
est: 129.44M (-9.2%)
|
128.14M
est: 157.63M (-18.7%)
|
123.90M
est: 194.79M (-36.4%)
|
131.67M
est: 218.55M (-39.7%)
|
192.22M
est: 148.36M (+29.6%)
|
182.13M
182.13M – 182.13M
+22.8% YoY
|
213.84M
213.84M – 213.84M
+17.4% YoY
|
251.17M
251.17M – 251.17M
+17.5% YoY
|
| EPS |
0.41
est: 0.54 (-23.6%)
|
0.42
est: 0.58 (-27.1%)
|
0.37
est: 0.78 (-52.7%)
|
0.38
est: 0.90 (-58.0%)
|
0.43
est: 0.57 (-24.7%)
|
0.62
0.62 – 0.62
+8.3% YoY
|
0.80
0.80 – 0.80
+29.0% YoY
|
0.97
0.97 – 0.97
+21.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chuanglong Yao | Vice Chairman, Chief Executive Officer & President | 2M | male |
| Yuyan Zheng | Vice President & Executive Director | 1M | female |
| Hanzi Zhang | Chief Financial Officer & Executive Director | 634.2K | female |
| Zhijie Lin | Vice President | 217.1K | male |
| Jiexi Yao | Company Secretary | — | female |
| Wai Ling Wong | Joint Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2289.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
